NICE guidance published today recommends leniolisib (also called Joenja and made by Pharming) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in people 12 years and over.

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...

Our highly specialised technologies (HST) programme is designed specifically to evaluate technologies for ultra-rare, debilitating conditions. It helps encourage research and innovation in areas where ...

NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is ...

While annual physical checks already take place for people with long-term conditions, we've found that BMI and waist-to-height measurements aren't consistently recorded. Our new approach addresses ...

The National Institute for Health and Care Excellence (NICE) is producing late-stage assessment guidance on Intermittent urethral catheters for chronic incomplete bladder emptying in adults: ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...

A list of downloadable documents created during development.

A list of downloadable documents created during development.